Medical device company Artivion (NYSE:AORT) will be reporting results this Thursday afternoon. Here’s what to look for.
Artivion beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $113.4 million, up 18.4% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.
Is Artivion a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Artivion’s revenue to grow 20.2% year on year to $117 million, improving from the 3.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.18 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Artivion has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.4% on average.
Looking at Artivion’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Envista delivered year-on-year revenue growth of 15%, beating analysts’ expectations by 10.6%, and Neogen reported a revenue decline of 2.8%, topping estimates by 7.2%. Envista traded up 17.8% following the results while Neogen was also up 30.4%.
Read our full analysis of Envista’s results here and Neogen’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Artivion is down 4.1% during the same time and is heading into earnings with an average analyst price target of $51.71 (compared to the current share price of $40.94).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.